1932

Abstract

Papillary thyroid microcarcinoma (PMC) is defined as papillary thyroid carcinoma ≤10 mm. Active surveillance of PMC without high-risk features, such as clinical node metastasis, distant metastasis, and clinical evidence of significant extrathyroid extension, was initiated in two Japanese hospitals in the mid-1990s. This strategy was incorporated into guidelines in Japan in 2010 and in the United States in 2015. In studies conducted by the two hospitals, most PMCs grew very slowly or did not grow, and none of the patients during active surveillance showed distant metastasis or died of thyroid carcinoma. Furthermore, none of the patients who underwent surgery after progression signs were detected showed significant recurrence. Therefore, we conclude that active surveillance should be the first line in management of low-risk PMC, because it is safer and less costly than immediate surgery. Active surveillance helps in avoiding adverse events of surgery and is an economical strategy.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051517-125510
2019-01-27
2024-06-12
Loading full text...

Full text loading...

/deliver/fulltext/med/70/1/annurev-med-051517-125510.html?itemId=/content/journals/10.1146/annurev-med-051517-125510&mimeType=html&fmt=ahah

Literature Cited

  1. 1.  Ito Y, Miyauchi A 2007. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat. Clin. Pract. Endocrinol. Metab. 3:3240–48
    [Google Scholar]
  2. 2.  Takebe K, Date M, Yamamoto N 1994. 超音波を用いた甲状腺癌検診の実際とその問題点. [Mass screening for thyroid cancer with ultrasonography.]. Karkinos 7:309–17
    [Google Scholar]
  3. 3.  Ito Y, Miyauchi A, Oda H et al. 2016. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: Was immediate surgery necessary?. World J. Surg. 40:3523–28
    [Google Scholar]
  4. 4.  Davies L, Welch HG 2006. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:182164–67
    [Google Scholar]
  5. 5.  Davies L, Welch HG 2014. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140:4217–22
    [Google Scholar]
  6. 6.  Ahn HS, Kim HJ, Welch HG 2014. Korea's thyroid-cancer “epidemic”—screening and overdiagnosis. N. Engl. J. Med. 371:191765–67
    [Google Scholar]
  7. 7.  Vaccarella S, Franceschi S, Bray F et al. 2016. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375:7614–17
    [Google Scholar]
  8. 8.  Oda H, Miyauchi A, Ito Y et al. 2016. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 26:1150–58
    [Google Scholar]
  9. 9.  Takami H, Ito Y, Okamoto T et al. 2011. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J. Surg. 35:1111–21
    [Google Scholar]
  10. 10.  Haugen BR, Alexander EK, Bible KC et al. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:11–133
    [Google Scholar]
  11. 11.  Ito Y, Miyauchi A, Kudo T et al. 2018. Trends in the implementation of active surveillance for low-risk papillary thyroid microcarcinomas at Kuma Hospital: gradual increase and heterogeneity in the acceptance of this new management option. Thyroid 28:4488–95
    [Google Scholar]
  12. 12.  Ito Y, Uruno T, Nakano K et al. 2003. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:4381–87
    [Google Scholar]
  13. 13.  Uruno T, Miyauchi A, Shimizu K et al. 2005. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J. Surg. 29:4483–86
    [Google Scholar]
  14. 14.  Ito Y, Tomoda C, Uruno T et al. 2004. Papillary microcarcinoma of the thyroid: How should it be treated?. World J. Surg. 28:5498–501
    [Google Scholar]
  15. 15.  Ito Y, Miyauchi A, Inoue H et al. 2010. An observation trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 34:128–35
    [Google Scholar]
  16. 16.  Ito Y, Miyauchi A, Kihara M et al. 2014. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:127–34
    [Google Scholar]
  17. 17.  Ito Y, Miyauchi A, Kihara M et al. 2018. Overall survival of papillary thyroid carcinoma patients: a single institution long-time follow-up of 5897 patients. World J. Surg. 42:3615–22
    [Google Scholar]
  18. 18.  Miyauchi A, Kudo T, Ito Y et al. 2018. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 163:148–52
    [Google Scholar]
  19. 19.  Sugitani I, Toda K, Yamada K et al. 2010. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34:61222–31
    [Google Scholar]
  20. 20.  Fukuoka O, Sugitani I, Ebina A et al. 2016. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J. Surg. 40:3529–37
    [Google Scholar]
  21. 21.  Sugitani I, Fujimoto Y, Yamada K 2014. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J. Surg. 38:3673–78
    [Google Scholar]
  22. 22.  Shindo H, Amino N, Ito Y et al. 2014. Papillary thyroid microcarcinoma might progress during pregnancy. Thyroid 24:5840–44
    [Google Scholar]
  23. 23.  Ito Y, Miyauchi A, Kudo T et al. 2016. Effects of pregnancy on papillary microcarcinoma of the thyroid re-evaluated in the entire patient series at Kuma Hospital. Thyroid 26:1156–60
    [Google Scholar]
  24. 24.  Oda H, Miyauchi A, Ito Y et al. 2017. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr. J 64:159–64
    [Google Scholar]
  25. 25.  Brito JP, Ito Y, Miyauchi A et al. 2016. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 26:1144–49
    [Google Scholar]
  26. 26.  Nickel B, Brito JP, Barratt A et al. 2017. Clinicians’ view on management and terminology for papillary thyroid microcarcinoma: a qualitative study. Thyroid 27:5661–71
    [Google Scholar]
  27. 27.  Nickel B, Brito JP, Moynihan R et al. 2018. Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer 18:1242
    [Google Scholar]
  28. 28.  Tuttle RM, Fagin JA, Minkowitz G et al. 2017. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol. Head Neck Surg. 143:101015–20
    [Google Scholar]
  29. 29.  Kwon H, Oh HS, Kim M et al. 2017. Active surveillance for patients with papillary thyroid microcarcinoma: a single center's experience in Korea. J. Clin. Endocrinol. Metab. 102:61917–25
    [Google Scholar]
  30. 30.  Kim HI, Jang HW, Ahn HS et al. 2018. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J. Clin. Endocrinol. Metab. 103:2446–51
    [Google Scholar]
  31. 31.  Yabuta T, Matsuse M, Hirokawa M et al. 2017. TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance. Thyroid 27:91206–7
    [Google Scholar]
  32. 32.  Xing A, Liu R, Liu X et al. 2014. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 32:252718–26
    [Google Scholar]
  33. 33.  Hirokawa M, Kudo T, Ota H et al. 2016. Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance. Endocr. J 63:9805–10
    [Google Scholar]
  34. 34.  Miyauchi A 2016. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J. Surg. 40:1516–22
    [Google Scholar]
  35. 35.  Miyauchi A, Ito Y, Oda H 2018. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid 28:123–31
    [Google Scholar]
/content/journals/10.1146/annurev-med-051517-125510
Loading
/content/journals/10.1146/annurev-med-051517-125510
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error